Business
Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting
PALO ALTO, Calif., Feb. 9, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and
About this update from Kodiak Sciences Inc
[{"type":"text","content":"PALO ALTO, Calif., Feb. 9, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that a presentation will be made at the upcoming Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting including clinical data from Kodiak's investigational therapy KSI-301 (tarcocimab tedromer) and an update on Kodiak's pipeline of Antibody Biopolymer Conjugate (ABC) development programs.\nDetails of the presentation are as follows:\nTitle: Update on KSI-301 (tarcocimab tedromer) and Antibody Biopolymer Conjugate Development Programs\nPresenter: Diana V. Do, M.D., Professor of Ophthalmology, Vice Chair of Clinical Affairs, Byers Eye Institute, Stanford University School of Medicine, Stanford, CA\nPresentation date and time: February 11, 2023; 1:10 PM ET\n\"We continue to make strong progress executing multiple trials across the tarcocimab (KSI-301) clinical program. We anticipate four Phase 3 clinical study readouts later this year, in approximately 3Q2023. Building on the unique durability shown in BEACON, our positive Phase 3 study in retinal vein occlusion where we doubled the treatment interval for all patients, we look forward to the results across the broader Phase 3 program in which we explore 5- and 6- month durability in patients with diabetic eye disease,\" said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences.\n\"We are also pleased to have successfully opened the IND for KSI-501, our second product candidate built from the ABC platform. KSI-501 is a potential first-in-class bispecific ABC that is designed to inhibit two powerful pathophysiologic mechanisms in retinal disease, VEGF and IL-6. With the IND cleared by the US FDA, we plan to initiate the Phase 1 study shortly. We look forward to engaging with the retina community as we actively develop this new agent which has the potential to bring additional benefits to patients with a number of retinal diseases including diabetic eye disease, neovascular macular degeneration and uveitic macular edema.\"\nKodiak plans to post the presentation slides on the \"Events and Presentations\" section of Kodiak's website at http://ir.kodiak.com/ at the beginning of the presentation.\nAbout tarcocimab t...